Related Experiment Video

Updated: Aug 7, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic

Jessica Stoeckel1, John G Hay

  • 1New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

Current Opinion in Molecular Therapeutics
|June 16, 2006
PubMed

Insights

Oncolytics Biotech is developing Reolysin, an oncolytic reovirus therapy, for multiple Ras-mediated cancers. Clinical trials for malignant glioma are ongoing, showing potential for treating various solid tumors and hematological cancers.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Ras-mediated cancers represent a significant unmet medical need.
  • Oncolytic viruses are a promising therapeutic strategy targeting cancer cells.
  • Reolysin (Reosyn) is an oncolytic reovirus therapy under development by Oncolytics Biotech.

Purpose of the Study:

  • To evaluate the potential of Reolysin as a treatment for various Ras-mediated cancers.
  • To investigate the efficacy of Reolysin in treating solid tumors and hematological malignancies.
  • To assess the safety and tolerability of Reolysin in clinical trials.

Main Methods:

  • Development of oncolytic reovirus therapy (Reolysin, Reosyn).
  • Targeting a range of Ras-mediated cancers including glioma, pancreatic, prostate, breast, lung, colon, bladder, ovarian, hematological cancers, melanoma, and childhood sarcoma.
  • Conducting Phase I/II clinical trials in recurrent malignant glioma since 2002.

Main Results:

  • Reolysin targets a broad spectrum of Ras-mediated cancers.
  • Clinical trials initiated in 2002 for recurrent malignant glioma.
  • Potential application in treating diverse oncological indications.

Conclusions:

  • Oncolytic reovirus therapy holds promise for treating various cancers.
  • Reolysin is a potential therapeutic agent for Ras-driven malignancies.
  • Ongoing clinical research aims to establish Reolysin's efficacy and safety.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...